A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs TSR 022 (Primary)
  • Indications Solid tumours; Tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors TESARO
  • Most Recent Events

    • 09 Aug 2017 Dose escalation part of this trial has been completed, as per a TESARO Inc. media release.
    • 10 Jun 2017 Biomarkers information updated
    • 12 May 2017 Planned number of patients changed from 402 to 447.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top